Futura Medical's MED3000 erectile dysfunction gel gets OTC approval in the Kingdom of Saudi Arabia, where Switzerland's Labatec Pharma has the rights to commercialize the product under the Eroxon brand. 

Haleon steps into the US OTC erectile dysfunction market with a commercialization deal for Futura's drug-free MED3000 gel, recently approved by the FDA as a de novo medical device. 

According to Futura's UK distributor, the recent launch of its Eroxon drug-free erectile dysfunction gel has been an outstanding success. Ceuta's Jon Connolly described the strategy behind the launch at a recent investor event. 

While Intercept is calling it quits in NASH with its FXR agonist obeticholic acid following a second complete response letter, other companies are staying the course with Phase II molecules in the class.